Global Leading Market Research Publisher QYResearch announces the release of its latest report “Microcrystalline Cellulose Core Pellet – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Microcrystalline Cellulose Core Pellet market, including market size, share, demand, industry development status, and forecasts for the next few years.
Addressing core industry needs: Controlled-release oral formulations require inert, compressible, and biocompatible pellet cores that can be uniformly coated for sustained drug delivery. Microcrystalline cellulose (MCC) core pellets solve this with excellent compressibility, flowability, and moldability, enabling precise API loading and consistent release profiles. Key drivers include generic extended-release drugs, patient compliance, and multi-particulate formulations.
The global market for Microcrystalline Cellulose Core Pellet was estimated to be worth US$ 132 million in 2025 and is projected to reach US$ 199 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production is approximately 16,500 tons, with an average price of US$ 7,550 per ton.
The Microcrystalline Cellulose Core Pellet is a drug carrier made primarily from microcrystalline cellulose, commonly used in the formulation of oral controlled-release or sustained-release drug preparations. Microcrystalline cellulose possesses excellent compressibility, flowability, and moldability, making it an ideal material for the core of the formulation. By encapsulating the active pharmaceutical ingredient (API) in the microcrystalline cellulose core, the release rate of the drug can be effectively controlled, thereby extending the therapeutic duration and reducing side effects. Additionally, microcrystalline cellulose has good biocompatibility, allowing safe drug release in the gastrointestinal tract.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098149/microcrystalline-cellulose-core-pellet
Market Segmentation & Key Players
The Microcrystalline Cellulose Core Pellet market is segmented as below:
Leading Suppliers: Colorcon, JRS, FREUND Corp, MB Sugars and Pharmaceuticals Pvt, Meenaxy Pharma Private Limited, Anhui Sunhere Pharmaceutical Excipients, Asahi Kasei Chemicals, Yuekang Pharmaceutical Group, Hangzhou Gaocheng Biotech & Health, Jiangsu Dongsheng Pharmaceutical Technology, Zhuhai TOPCHAIN Pharmaceutical.
Segment by Type: Particle Size Below 500 μm | Particle Size 500–1000 μm | Particle Size Above 1000 μm
Segment by Application: Tablet | Capsule
Exclusive Industry Insights
Discrete extrusion-spheronization process: MCC core pellets are manufactured via extrusion-spheronization – MCC powder (typically 80–120μm particle size) is wet-massed, extruded through a screen (0.5–1.5mm), and spheronized into uniform spheres. MCC’s high water absorption capacity (2–3x its weight) makes it ideal for this process.
Technical differentiation – particle size segments:
- Below 500 μm (18% revenue): Fine pellets for fast-disintegrating multi-particulate capsules. For pediatric and geriatric formulations.
- 500–1000 μm (62% revenue): Standard range, optimal for subsequent coating (enteric, sustained-release). Largest segment.
- Above 1000 μm (20% revenue): Large pellets for high-dose drugs, once-daily extended-release. Fastest-growing (CAGR 6.8%).
Recent 6-month data (Oct 2025 – Mar 2026):
- Tablet application dominates (68% revenue) – compressed multi-particulate tablets (MUPS).
- Capsule application fastest-growing (CAGR 6.5%) – multi-particulate capsules with blend of release profiles.
- High-density MCC grades (for higher API loading) grew 18% YoY.
User case – Generic cardiovascular drug manufacturer (India, 100 tons/year): Developing sustained-release formulation using MCC core pellets (500–700μm) with ethylcellulose coating achieved 24-hour extended release, reducing dosing from 2x to 1x daily. Bioequivalence to branded reference achieved. Micro-pellet cost: US$ 8.50/kg; finished dose margin: 65%.
Application insights: Tablet (68%) – MUPS tablets (multi-particulate), matrix tablets with embedded pellets, disintegrating tablets. Capsule (32%) – multi-particulate capsules (immediate + extended-release blend), sprinkle capsules.
Critical performance requirements:
- Sphericity: Aspect ratio <1.2 for uniform coating.
- Porosity: 30–40% for optimal liquid absorption.
- Friability: <0.5% weight loss.
- Yield strength: Sufficient to withstand compression into tablets.
Regional snapshot: North America leads with 44% revenue share (high-value extended-release formulations). Europe holds 26%. Asia-Pacific fastest-growing (CAGR 7.2%), driven by generic drug manufacturing.
Conclusion
The microcrystalline cellulose core pellet market grows steadily, driven by generic extended-release formulations, MUPS tablet technology, and multi-particulate capsules. Success depends on sphericity control, particle size uniformity, and compression robustness. The projected US$ 199 million market by 2032 appears achievable.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
